Nucleic acids encoding chimera botulinum toxin type E
AssigneeAllergan, Inc.
InventorsEster Fernandez-Salas, Lance E. Steward, Todd Herrington, K. Roger Aoki
Life of this patent
Estimating the term…
Abstract
The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xExxxLL (SEQ ID NO: 112) at the C-terminus, wherein x is any amino acid.
Claims12
A nucleic acid comprising a region that encodes a modified toxin comprising a modified light chain of a botulinum toxin type E, wherein the modification to the botulinum toxin type E light chain is the addition of one or more amino acid sequences comprising SEQ ID NO:
- 120 within the N-terminal 30 amino acids of a wild-type botulinum toxin type E light chain of SEQ ID NO:
- 136 and the addition of one or more leucine-based motifs of SEQ ID NO:
- 112 within the C-terminal 50 amino acids of a wild-type botulinum toxin type E light chain of SEQ ID NO:
- 136,
- wherein the addition of the amino acid sequence comprising SEQ ID NO:
- 120 increases biological half-life of the modified toxin relative to an identical modified toxin without the additional amino acid sequence comprising SEQ ID NO:
- 120, and,
- wherein the addition of the leucine-based motif of SEQ ID NO:
- 112 increases biological half-life of the modified toxin relative to an identical modified toxin without the additional leucine-based motif comprising SEQ ID NO:
- 112.
A nucleic acid comprising a region that encodes a modified toxin comprising a modified light chain of SEQ ID NO:
- 136, wherein one or more of SEQ ID NO:
- 120 occur within the N-terminal 30 amino acids of the light chain, and one or more of SEQ ID NO:
- 112 occur within the C-terminal 50 amino acids of the light chain,
- wherein the addition of one or more SEQ ID NO:
- 120 increases biological half-life of the modified toxin relative to an identical modified toxin without the addition of one or more SEQ ID NO:
- 120, and,
- wherein the addition of one or more SEQ ID NO:
- 112 increases biological half-life of the modified toxin relative to an identical modified toxin without the addition of one or more SEQ ID NO:
- 112.
Dependencies are inferred from the claim text.